Product Information
LYLEQ 0.35 MG TABLET is a generic product labeled by Afaxys Pharma, LLC, priced at $0.0924 per EA under NDC 50102030013. Its NADAC has been published 284 times since Apr 28, 2021.
FDA first approved this application on Sep 23, 2016. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.35 mg/1
Manufacturer
Afaxys Pharma, LLCNDC
50102030013
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NORETHINDRONEApproval Type
Generic (ANDA)
FDA Application
ANDA207304FDA Approved
9/23/2016
TE Code
AB1
On Market Since
9/23/2016
Pharmacological Classes
Price Statistics
The NADAC for LYLEQ 0.35 MG TABLET has been published 284 times since Apr 28, 2021, and over the history we have for it it has declined 59.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0924 per EA |
|---|---|
| All-time high | $0.2293 (May 12, 2021) |
| All-time low | $0.0691 (Nov 20, 2024) |
| 52-week high | $0.0945 |
| 52-week low | $0.0849 |
| Median price | $0.1183 |
| Average price | $0.1250 |
| Largest weekly change | +43.4% (Aug 21, 2024) |
| Weeks tracked | 284 |
| Tracking since | Apr 28, 2021 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Afaxys Pharma, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
NORETHINDRONE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Progestin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LYLEQ 0.35 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LYLEQ 0.35 MG TABLET, manufactured by Afaxys Pharma, LLC, is $0.0924 per EA (NDC 50102030013), effective Sep 30, 2026.
How has the price of LYLEQ 0.35 MG TABLET changed over time?
Over the history we have for it, the NADAC for LYLEQ 0.35 MG TABLET has declined 59.7%. It has been tracked across 284 weekly CMS publications since Apr 28, 2021.
What are the highest and lowest recorded NADAC prices for LYLEQ 0.35 MG TABLET?
Since Apr 28, 2021, the NADAC for LYLEQ 0.35 MG TABLET has ranged from a low of $0.0691 (Nov 20, 2024) to a high of $0.2293 (May 12, 2021), with a median of $0.1183 per EA.
Are there cheaper alternatives to LYLEQ 0.35 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ERRIN 0.35 MG TABLET, is $0.0906 per EA — about 2% below LYLEQ 0.35 MG TABLET.
Who manufactures LYLEQ 0.35 MG TABLET?
LYLEQ 0.35 MG TABLET (NDC 50102030013) is labeled by Afaxys Pharma, LLC, and CMS classifies it as a generic product.